Plain-English translation of NCT07287345 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a small pilot study testing whether colchicine—a medication that reduces inflammation—can help lower inflammation levels and prevent irregular heartbeat after coronary artery bypass graft surgery. Half of the participants will receive colchicine along with their standard care, while the other half will receive a placebo (a fake pill) with their standard care. Neither you nor the study team will know which group you're in.
After heart bypass surgery, many patients develop inflammation and irregular heartbeats, which can complicate recovery. This study wants to see if this medication might help prevent those complications, paving the way for larger research studies in the future.
You likely qualify if…
You likely don't qualify if…
You will take a study capsule (either the medication or placebo) along with your regular care before and after your bypass surgery. Blood samples and health information will be collected before surgery and then at five time points after surgery: at 24, 48, 72, and 96 hours, and again at 10 days or hospital discharge (whichever comes first). The study team will track your inflammation levels, whether you develop an irregular heartbeat, and any side effects.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States
Post-approval monitoring
Sponsor
Ayesha Ather
Enrollment target
~24 participants
Started
January 2026
Primary completion
December 2026
Age range
18 Years – 99 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ayesha Ather
University of Kentucky
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.